Dementia in Down syndrome: unique insights for Alzheimer disease research

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Nature Reviews Neurology

• Publication date

  2019-02-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41582-018-0132-6PMID 30733618PMCID PMC8061428
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Co‐occurring medical conditions in adults with Down syndrome: A systematic review toward the development of health care guidelines. Part II

  2020cited by this paper
• DEGENERATION

  2020cited by this paper
• Mitochondria as pharmacological targets in Down syndrome.

  2018cited by this paper
• Dysregulation of neurotrophin signaling in the pathogenesis of Alzheimer disease and of Alzheimer disease in Down syndrome.

  2018cited by this paper
• Review: Somatic mutations in neurodegeneration

  2018cited by this paper
• Amyloid toxicity in Alzheimer’s disease

  2018cited by this paper
• Alzheimer disease: Epigenetics links ageing with Alzheimer disease

  2018cited by this paper
• Dysfunction of autophagy and endosomal‐lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer's Disease

  2018cited by this paper
• Co‐occurring medical conditions in adults with Down syndrome: A systematic review toward the development of health care guidelines

  2018cited by this paper
• Prevalence of physical conditions and multimorbidity in a cohort of adults with intellectual disabilities with and without Down syndrome: cross-sectional study

  2018cited by this paper
• Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism.

  2018cited by this paper
• Down syndrome, beta-amyloid and neuroimaging.

  2018cited by this paper
• Age-dependent association of thyroid function with brain morphology and microstructural organization: evidence from brain imaging.

  2018cited by this paper
• Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome.

  2017cited by this paper
• Increased levels of plasma total tau in adult Down syndrome

  2017cited by this paper
• APP mouse models for Alzheimer's disease preclinical studies

  2017cited by this paper
• The discovery of Alzheimer‐causing mutations in the APP gene and the formulation of the “amyloid cascade hypothesis”

  2017cited by this paper
• The Arizona Cognitive Test Battery for Down Syndrome: Test-Retest Reliability and Practice Effects.

  2017cited by this paper
• Clinical meaningfulness of Alzheimer's Disease Assessment Scale–Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors

  2017cited by this paper
• Blood Beta-Amyloid and Tau in Down Syndrome: A Comparison with Alzheimer’s Disease

  2017cited by this paper
• Neuropsychological Measures that Predict Progression from Mild Cognitive Impairment to Alzheimer's type dementia in Older Adults: a Systematic Review and Meta-Analysis

  2017cited by this paper
• Epileptic activity in Alzheimer's disease: causes and clinical relevance.

  2017cited by this paper
• Candidate gene analysis for Alzheimer's disease in adults with Down syndrome.

  2017cited by this paper
• Cognitive decline and dementia in Down syndrome

  2017cited by this paper
• The Role of Neuropsychology in the Assessment of the Cognitively Impaired Elderly.

  2017cited by this paper
• Perimenopause and emergence of an Alzheimer’s bioenergetic phenotype in brain and periphery

  2017cited by this paper
• The facial morphology in Down syndrome: A 3D comparison of patients with and without obstructive sleep apnea

  2017cited by this paper
• Endocrine Autoimmunity in Down's Syndrome.

  2017cited by this paper
• A prospective 20‐year longitudinal follow‐up of dementia in persons with Down syndrome

  2017cited by this paper
• PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI)

  2017cited by this paper
• Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.

  2017cited by this paper
• Pharmacotherapeutic Considerations for Individuals with Down Syndrome

  2017cited by this paper
• Oxidative stress and the amyloid beta peptide in Alzheimer’s disease

  2017cited by this paper
• Cerebrovascular pathology in Down syndrome and Alzheimer disease

  2017cited by this paper
• The brain map of gait variability in aging, cognitive impairment and dementia—A systematic review

  2017cited by this paper
• Novel presenilin 1 mutation (p.F386I) in a Chinese family with early-onset Alzheimer's disease.

  2017cited by this paper
• Thyroid dysfunction in patients with Down syndrome: Results from a multi‐institutional registry study

  2017cited by this paper
• Longitudinal telomere shortening and early Alzheimer's disease progression in adults with down syndrome

  2017cited by this paper
• Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal‐dominant Alzheimer's disease

  2017cited by this paper
• The Early Presentation of Dementia in People with Down Syndrome: a Systematic Review of Longitudinal Studies

  2017cited by this paper
• Apolipoprotein E and Alzheimer’s disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins

  2017cited by this paper
• Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms

  2017cited by this paper
• Obstructive sleep apnoea and Alzheimer’s disease: In search of shared pathomechanisms

  2017cited by this paper
• Version 3 of the Alzheimer Disease Centers’ Neuropsychological Test Battery in the Uniform Data Set (UDS)

  2017cited by this paper
• Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome

  2017cited by this paper
• Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome☆

  2017cited by this paper
• Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer’s disease: a rationale for multi-nutrient dementia prevention

  2017cited by this paper
• Motoric Cognitive Risk Syndrome: Predictor of Dementia and Age-Related Negative Outcomes

  2017cited by this paper
• Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome

  2017cited by this paper
• Rodent models in Down syndrome research: impact and future opportunities

  2017cited by this paper
• Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-β Burden in Down Syndrome

  2017cited by this paper
• The clinical and neurobehavioral course of Down syndrome and dementia with or without new-onset epilepsy.

  2017cited by this paper
• The importance of understanding individual differences in Down syndrome

  2016cited by this paper
• Assessing Specific Cognitive Deficits Associated with Dementia in Older Adults with Down Syndrome: Use and Validity of the Arizona Cognitive Test Battery (ACTB)

  2016cited by this paper
• Incidence and impact of subclinical epileptiform activity in Alzheimer's disease

  2016cited by this paper
• Down syndrome and the complexity of genome dosage imbalance

  2016cited by this paper
• The pattern of amyloid accumulation in the brains of adults with Down syndrome

  2016cited by this paper
• Obstacle crossing in 7-9-year-old children with Down syndrome.

  2016cited by this paper
• Gait dyspraxia as a clinical marker of cognitive decline in Down syndrome: A review of theory and proposed mechanisms.

  2016cited by this paper
• Stakeholder Buy-In and Physician Education Improve Adherence to Guidelines for Down Syndrome.

  2016cited by this paper
• Neuronal activity enhances tau propagation and tau pathology in vivo

  2016cited by this paper
• An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation

  2016cited by this paper
• Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer’s Disease: The Role of APP

  2016cited by this paper
• Improving Memory and Cognition in Individuals with Down Syndrome

  2016cited by this paper
• Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease?

  2016cited by this paper
• Trans-acting epigenetic effects of chromosomal aneuploidies: lessons from Down syndrome and mouse models

  2016cited by this paper
• The effects of normal aging on amyloid‐β deposition in nondemented adults with Down syndrome as imaged by carbon 11–labeled Pittsburgh compound B

  2016cited by this paper
• A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-β-Driven Inflammation in Down Syndrome.

  2016cited by this paper
• Dementia in Down's syndrome.

  2016cited by this paper
• Alzheimer’s disease in people with Down’s syndrome: the prospects for and the challenges of developing preventative treatments

  2016cited by this paper
• Periodontal disease's contribution to Alzheimer's disease progression in Down syndrome

  2016cited by this paper
• Dissociation of Down syndrome and Alzheimer's disease effects with imaging

  2016cited by this paper
• Proteolytic Cleavage of Apolipoprotein E in the Down Syndrome Brain

  2016cited by this paper
• Cognitive Profiles on the Severe Impairment Battery Are Similar in Alzheimer Disease and Down Syndrome With Dementia

  2016cited by this paper
• The amyloid hypothesis of Alzheimer's disease at 25 years

  2016cited by this paper
• Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.

  2016cited by this paper
• Pharmacological interventions for cognitive decline in people with Down syndrome.

  2015cited by this paper
• The meaning of ‘community’ in the lives of people with intellectual disabilities: an historical perspective

  2015cited by this paper
• The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease.

  2015cited by this paper
• Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study

  2015cited by this paper
• Down Syndrome Disintegrative Disorder

  2015cited by this paper
• Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease.

  2015cited by this paper
• Dissecting Alzheimer disease in Down syndrome using mouse models

  2015cited by this paper
• Vascular contributions to cognitive impairment and dementia including Alzheimer's disease

  2015cited by this paper
• Mosaicism for trisomy 21: A review

  2015cited by this paper
• Noradrenergic System in Down Syndrome and Alzheimer's Disease A Target for Therapy.

  2015cited by this paper
• Cerebal overinhibition could be the basis for the high prevalence of epilepsy in persons with Down syndrome.

  2015cited by this paper
• Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease?

  2015cited by this paper
• Blood pressure levels and body mass index in Brazilian adults with Down syndrome

  2015cited by this paper
• Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

  2015cited by this paper
• Mechanisms of epigenetic and cell-type specific regulation of Hey target genes in ES cells and cardiomyocytes.

  2015cited by this paper
• Down syndrome and Alzheimer's disease: Common pathways, common goals

  2015cited by this paper
• Slowing the progression of Alzheimer's disease; what works?

  2015cited by this paper
• Role of Trisomy 21 Mosaicism in Sporadic and Familial Alzheimer's Disease.

  2015cited by this paper
• Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia

  2015cited by this paper
• Accelerated epigenetic aging in Down syndrome

  2015cited by this paper
• Alzheimer's disease risk genes and mechanisms of disease pathogenesis.

  2015cited by this paper
• Estrogen receptor β in Alzheimer's disease: From mechanisms to therapeutics.

  2015cited by this paper
• Candidate genes for Alzheimer's disease are associated with individual differences in plasma levels of beta amyloid peptides in adults with Down syndrome.

  2015cited by this paper
• A mouse model of Alzheimer's disease displays increased susceptibility to kindling and seizure‐associated death

  2015cited by this paper

• The cholinergic system exerts opposing effects on memory at different stages of disease progression in Alzheimer's and Down syndrome model systems

  2026cites this paper
• Probable cerebral amyloid angiopathy - related inflammation in a 32-year-old woman with down syndrome

  2026cites this paper
• White matter aging across the lifespan in Down syndrome: developmental origins, Alzheimer's disease progression, and therapeutic implications

  2026cites this paper
• Brain volume trajectories in Down syndrome and autosomal dominant Alzheimer's disease

  2026cites this paper
• Levetiracetam prevents Aβ production through SV2a-dependent modulation of APP processing in Alzheimer's disease models.

  2026cites this paper
• 'Name It to Tame It': Dementia Diagnostic Procedure in Austrian Care Facilities for People With Intellectual Disabilities. An Interview Study.

  2026cites this paper
• Alzheimer’s Disease and Contemporary Therapeutic Approaches: Recent Advances in Natural Products

  2026cites this paper
• Neuroinflammation as a driver of Down syndrome-associated Alzheimer's disease.

  2026cites this paper
• Habilitative and rehabilitative educational interventions as protective factors against cognitive decline in adults with Down syndrome: A retrospective study.

  2026cites this paper
• The impact of congenital heart disease on the timing of Alzheimer's disease in Down syndrome

  2026influential citation
• Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 iPSC-derived neural cells

  2026cites this paper
• Temporal dynamics of white matter hyperintensities related to Alzheimer's disease in adults with Down syndrome

  2026cites this paper
• Spatial abilities in aging adults with Down syndrome

  2026cites this paper
• Extending the Age-Range of the Diagnostic Interview for Adolescents and Adults with Intellectual Disability (DIAAID): An Interview Schedule of Mental Disorders

  2025cites this paper
• The history of Down syndrome–associated Alzheimer's disease; past, present, and future

  2025cites this paper
• Resistance and resilience to Alzheimer's disease in Down syndrome

  2025cites this paper
• Enhancing protein O-GlcNAcylation in down syndrome mice mitigates memory dysfunctions through the rescue of mitochondrial bioenergetics, stress responses and pathological markers

  2025cites this paper
• Alzheimer's Disease Research Center Down Syndrome Cores: Experience from two sites

  2025cites this paper
• Lifestyle Composite and Resilience to Alzheimer's Disease Pathology in Down Syndrome

  2025influential citation
• Plasma p‐tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease

  2025cites this paper
• Telomere Biology, Erosion, and Age-Related Conditions: Insights from Down Syndrome and Other Telomere-Associated Disorders

  2025cites this paper
• Genome‐wide association analyses identify candidate loci for amyloid imaging and plasma biomarkers in adults with Down syndrome

  2025cites this paper
• Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model

  2025cites this paper
• Preliminary investigation of obstructive sleep apnea and Alzheimer’s disease in down syndrome

  2025cites this paper
• Neuropsychiatric signatures across the Alzheimer's disease continuum in Down syndrome and sporadic forms: A biomarker-driven comparison

  2025cites this paper
• The power of five - inositol polyphosphate 5-phosphatase gene mutations at the intersection of development and disease.

  2025cites this paper
• Cholinotrophic basal forebrain connectome dysfunction in Down syndrome with and without dementia

  2025cites this paper
• Genetically determined Alzheimer's disease research advances: The Down Syndrome & Autosomal Dominant Alzheimer's Disease 2024 Conference

  2025cites this paper
• The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome: A decade of discovery

  2025cites this paper
• Molecular cartography of the human down syndrome and trisomic mouse brain

  2025cites this paper
• Characterization of neurodegenerative pathologies in adult and pediatric subjects with Down syndrome

  2025cites this paper
• A myeloid trisomy 21-associated gene variant is protective from Alzheimer’s disease

  2025cites this paper
• Prevalence and Modifiable Risk Factors of Dementia in People With Down Syndrome: Cross‐Sectional Study of Japan in Collaboration With the Intellectual Diversity for Goodness Research Consortium (INDIGO‐2019)

  2025cites this paper
• Early Markers for Dementia in the Intellectual Disability Population: A Systematic Literature Review

  2025cites this paper
• Reviewing the possible connection between cerebral amyloid angiopathy and blood–brain barrier integrity in Down syndrome

  2025cites this paper
• Trends in the Prevalence of Down Syndrome (Trisomy 21) in Texas by Maternal Race/Ethnicity and Maternal Age Groups, 1999–2020

  2025cites this paper
• Antisense oligonucleotides directed against App and Rab5 normalized endosomal Rab activity and reversed DS‐AD‐linked degenerative phenotypes in the Dp16 mouse model of Down syndrome

  2025cites this paper
• The dependence of basal forebrain cholinergic neurons on NGF: The case in Alzheimer pathology.

  2025cites this paper
• Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study

  2025cites this paper
• Proteome Signature of Alzheimer-Like Phenotypes in Frontal Cortices From Young and Old Individuals With Down Syndrome

  2025cites this paper
• Serotonin-mediated regulation of mitophagy in Alzheimer's disease: mechanistic insights and therapeutic potential.

  2025cites this paper
• ALTERAÇÕES GENÉTICAS NO FETO: AS MUTAÇÕES NÃO-DISJUNTIVAS NA MEIOSE E SUA RELAÇÃO COM A INCIDÊNCIA DA SÍNDROME DE DOWN

  2025cites this paper
• Implications of Down Syndrome on Dental Management

  2025cites this paper
• Age and sex are associated with Alzheimer's disease neuropathology in Down syndrome

  2025cites this paper
• About genotype and allele distributions of APP promoter single-nucleotide polymorphisms

  2025cites this paper
• Genetic markers involved in neuroinflammation in Down syndrome: a systematic review

  2025cites this paper
• Plasma p-tau217 as a biomarker of Alzheimer’s disease pathology in individuals with Down syndrome

  2025cites this paper
• HSPA13 gene and microRNA-155: relationship between Down syndrome and Alzheimer’s disease

  2025cites this paper
• Mitochondrial Imbalance in Down Syndrome: A Driver of Accelerated Brain Aging?

  2025cites this paper
• Profiling hippocampal neuronal populations reveals unique gene expression mosaics reflective of connectivity-based degeneration in the Ts65Dn mouse model of Down syndrome and Alzheimer’s disease

  2025cites this paper
• Aging Unequally: Functional Age Disparities Between Developmental and Non-Developmental Disabilities

  2025cites this paper
• Benefits of Maternal Choline Supplementation on Aged Basal Forebrain Cholinergic Neurons (BFCNs) in a Mouse Model of Down Syndrome and Alzheimer’s Disease

  2025cites this paper
• A neuropathology case report of a woman with Down syndrome who remained cognitively stable: Implications for resilience to neuropathology

  2025cites this paper
• Amyloid neuropathy, tauopathy, decreased cholinergic and dopaminergic neurons, long-term memory and motor deficits, and sleep disturbance in motopsin deficient mice.

  2025cites this paper
• Down syndrome and a presenilin 2 variant: dual genetic risk of Alzheimer’s disease

  2025cites this paper
• Proactive Cognitive Stimulation for Younger Adults With Down Syndrome. A Feasibility Randomised Control Trial.

  2025cites this paper
• Tau protein aggregation: A therapeutic target for neurodegenerative diseases.

  2025cites this paper
• Single‐nucleus analysis reveals oxidative stress in Down syndrome basal forebrain neurons at birth

  2025cites this paper
• Alzheimer's disease diagnostic progression is associated with cerebrovascular disease and neuroinflammation in adults with Down syndrome

  2025cites this paper
• Genome‐wide association of tau neuroimaging and plasma biomarkers in adults with Down syndrome

  2025cites this paper
• The cholinotrophic system in Down syndrome.

  2025cites this paper
• Hyperactivation of RAB5 disrupts the endosomal Rab cascade leading to endolysosomal dysregulation in Down syndrome: A necessary role for increased APP gene dose

  2025cites this paper
• Development of Molecular Neuropathology in Down Syndrome across the Lifespan

  2025cites this paper
• Behavioral and psychological symptoms of dementia and Alzheimer’s disease progression in Down syndrome

  2025cites this paper
• Proteostasis Decline and Redox Imbalance in Age-Related Diseases: The Therapeutic Potential of NRF2

  2025cites this paper
• Imagine, Discover, Inspire: Proceedings of the 4th International Conference of the Trisomy 21 Research Society

  2025cites this paper
• Enhanced automated Alzheimer’s disease detection from MRI images by exploring handcrafted and transfer learning feature extraction methods

  2025cites this paper
• Single-nucleus analysis reveals oxidative stress in Down syndrome basal forebrain neurons at birth

  2025cites this paper
• Correlating hippocampal and amygdala volumes with neuropathological burden in Down syndrome and Alzheimer’s disease and related neurodegenerative pathologies using 7T postmortem MRI

  2025cites this paper
• Factors Associated With Alzheimer's Dementia Diagnosis and Survival in Down Syndrome

  2025cites this paper
• Nerve growth factor precursor alterations in neuron‐derived extracellular vesicles from individuals with Down syndrome along the Alzheimer's disease continuum

  2025cites this paper
• Blood‐based biomarkers for Alzheimer's disease in Down syndrome: A systematic review and meta‐analysis

  2025cites this paper
• Blood biomarkers in Down syndrome: Facilitating Alzheimer's disease detection and monitoring

  2024cites this paper
• Spatial and single-nucleus transcriptomic analysis of genetic and sporadic forms of Alzheimer’s disease

  2024cites this paper
• Comparison between DSQIID total / sub-item scores and plasma p-tau elevation in adults with Down’s syndrome

  2024cites this paper
• Plasma p-tau212 as a biomarker of sporadic and Down Syndrome Alzheimer’s disease

  2024cites this paper
• Levetiracetam prevents Aβ42 production through SV2a-dependent modulation of App processing in Alzheimer's disease models

  2024cites this paper
• What Can We Learn About Alzheimer's Disease from People with Down Syndrome?

  2024cites this paper
• Neuropathology of trisomy 21 mosaicism in a case with early‐onset dementia

  2024cites this paper
• The association of dementia risk symptoms and functional activity in adults with Down syndrome

  2024cites this paper
• The role of interferon signaling in neurodegeneration and neuropsychiatric disorders

  2024cites this paper
• Understanding Down Syndrome: A Systematic Review of Genetic, Clinical, and Cognitive Implications

  2024influential citation
• Familial cerebral amyloid disorders with prominent white matter involvement.

  2024cites this paper
• Down Syndrome Biobank Consortium: A perspective

  2024cites this paper
• Cerebrovascular disease is associated with Alzheimer’s plasma biomarker concentrations in adults with Down syndrome

  2024cites this paper
• Impaired glymphatic clearance is an important cause of Alzheimer’s disease

  2024cites this paper
• Biomarker-Based Precision Therapy for Alzheimer’s Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine

  2024cites this paper
• Analysis of microisolated frontal cortex excitatory layer III and V pyramidal neurons reveals a neurodegenerative phenotype in individuals with Down syndrome

  2024cites this paper
• V-ATPase Dysfunction in the Brain: Genetic Insights and Therapeutic Opportunities

  2024cites this paper
• Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome

  2024cites this paper
• Research progress on the protection and mechanism of active peptides in Alzheimer's disease and Parkinson's disease.

  2024cites this paper
• Characterization of white matter hyperintensities in Down syndrome

  2024cites this paper
• Brain insulin resistance in Down syndrome: Involvement of PI3K-Akt/mTOR axis in early-onset of Alzheimer's disease and its potential as a therapeutic target.

  2024cites this paper
• Transcranial photobiomodulation for neurodevelopmental disorders: a narrative review

  2024cites this paper
• Early oxidative stress and DNA damage in Aβ-burdened hippocampal neurons in an Alzheimer’s-like transgenic rat model

  2024cites this paper
• Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer’s disease with APPdup and Down syndrome

  2024cites this paper
• Not all plaques are created equal: Uncovering a unique molecular signature in Alzheimer’s disease

  2024cites this paper
• In vivo quasi-elastic light scattering detects molecular changes in the lenses of adolescents with Down syndrome.

  2024cites this paper
• Assessing the Relationship of Brain Metabolites to Cortical Thickness and Dementia Symptoms in Adults with Down Syndrome: A Pilot Study

  2024cites this paper
• Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

  2024cites this paper